Schedule

34th Annual Meeting Schedule

Thursday , Nov. 7, 2019
Session 100: Hematologic Malignancies
Organized in collaboration with the American Society of Hematology (ASH). 
Time: 1  5 p.m.
Co-Chairs:

Katayoun Rezvani, MD, PhD   The University of Texas MD Cancer Center
John M. Timmerman, MD University of California, Los Angeles

Poster Symposium
Time: 5:30  7:30 p.m.


Friday, Nov. 8, 2019 
Session 200: Update Session

Time:

 8:05 8:35 a.m.

Session 201: Richard V. Smalley, MD Memorial Lectureship

Time:

8:35 – 9:25 a.m.

Chair: 

Mario Sznol, MD – Yale School of Medicine

8:35 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

8:40 a.m. Traveling the Cancer Vaccine Road and Reaching My Destination
Olivera J. Finn, PhD – University of Pittsburgh School of Medicine
9:20 a.m.

Question & Answers
Olivera J. Finn, PhD – University of Pittsburgh School of Medicine

Session 202: Autoimmunity, Toxicity, and Cancer Immunotherapy

Time:

9:25 a.m. 12 p.m.

Co-Chairs:

Jarushka Naidoo, MD – Johns Hopkins Sidney Kimmel Cancer Center
Virginia Pascual, MD – Weill Cornell Medicine

9:25 a.m.

Introduction

9:30 a.m.

Clinical irAE

9:50 a.m.

Basic Mechanisms in Autoimmunity/ Novel, New Data on T cells

10:10 a.m.

Break

10:25 a.m.

Autoantibodies

10:45 a.m.

Colitis

11:05 a.m.

Abstract Presentation

11:20 a.m.

Abstract Presentation

11:35 a.m.

Panel Discussion

Session 203: Late-Breaking Abstract Session
Time:  12 12:30 p.m.
12 p.m. Abstract Presentation
12:15 p.m. Abstract Presentation
Lunch, Exhibits and Poster Viewing
Time: 12:30  2 p.m.
Concurrent Rapid Oral Abstract Presentations - Basic Research
Time: 12:45 1:45 p.m.
Concurrent Rapid Oral Abstract Presentations - Clinical
Time:  12:45 1:45 p.m.
Session 204: Immune Checkpoints: Newer Targets and Update on Combinations
Time:  2 4:20 p.m.
Co-Chairs:  Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
Ahmad A. Tarhini, MD, PhD – Emory University and Winship Comprehensive Cancer Center
2 p.m. Introduction
2:05 p.m. Targeting CD38 to optimize PD-1/PD-L1 and CTLA-4 Blockade Immunotherapy
2:25 p.m. Combinations: IL-2
2:45 p.m. The Emerging Role of TLR Agonists in Cancer Immunotherapy
3:05 p.m. Novel Targets: TIM-3
3:25 p.m. Immune Contexture and Immune Escape at Pre-Cancer Lesion Stages 
3:45 p.m. Abstract Presentation
4 p.m. Panel Discussion
4:15 p.m. Closing
Concurrent Session 205: Biology of T cells
Time: 4:50 6:15 p.m.
Co-Chairs: Rafi Ahmed, PhD – Emory University
Ana Carrizosa Anderson, PhD – Harvard Medical School
4:50 p.m. T cell Responses in Tumor, Chronic Antigen Stimulation, T cell Exhaustion
Dietmar Zehn, PhD, MD – Technical University of Munich
5:15 p.m. Single Cell Profiling of Anti-Tumor T cell Response
Enrico Lugli, PhD – Instituto Clinico Humanitas IRCCS
5:40 p.m. Biology of T cells 
6:05 p.m. Abstract Presentation
Concurrent Session 206: High Impact Clinical Trials
Time: 4:50 6:15 p.m.
4:50 p.m. Introduction
4:55 p.m. Abstract Presentation
5:10 p.m. Abstract Presentation
5:25 p.m. Abstract Presentation
5:40 p.m. Abstract Presentation
5:55 p.m. Abstract Presentation
6:10 p.m. Closing
Concurrent Session 207: Harnessing Antigen-Presenting cells to Boost Anti-Tumor Immunity
Time:  4:50 6:15 p.m.
Co-Chairs:  Matthew Krummel, PhD – University of California, San Francisco
Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT

4:50 p.m. DC Subsets,T cell Interactions, Tumor-Resident, and Murine Studies
5:10 p.m. Phagocytic cells, Migratory cells, and Human Studies
5:30 p.m. Basic Biology of Phagocytic cells
5:50 p.m. Abstract Presentation
6 p.m. Abstract Presentation
6:10 p.m. Abstract Question and Answer
Concurrent Session 208: Tumor Cell Atlas Efforts  Big Data
Time:  4:50 6:15 p.m.
Chair:  Orit Rozenblatt-Rosen, PhD – Broad Institute
4:50 p.m. Progression
5:05 p.m. Interactions
5:20 p.m. Tutorial
5:35 p.m. Computational
5:50 p.m. Abstract Presentation
6:05 p.m. Question & Answers
Concurrent Session 209: Virus Driven Cancers
Time:

4:50 6:15 p.m.

Co-Chairs:

Robert Ferris, MD, PhD – UPMC Hillman Cancer Center
Weijing Sun, MD, FACP – University of Kansas Medical Center

4:50 p.m.

HPV and Head and Neck Cancers

5:05 p.m.

EBV and Cancers

5:20 p.m.

Liver Cancer

5:35 p.m.

Merkel Cell Carcinoma
Suzanne L. Topalian, MD – Johns Hopkins University School of Medicine

5:50 p.m.

Abstract Presentation

6 p.m.

Abstract Presentation

6:10 p.m. Question & Answers


Saturday, Nov. 9, 2019 

Session 300: Update Session

Time: 

7:55 8:25 a.m.

Session 301: Update Session

Time:

8:25 – 8:55 a.m.

Session 302: Keynote Address

Time:

8:55 9:45 a.m.

Chair:

Mario Sznol, MD – Yale School of Medicine

8:55 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

9 a.m.

Using Advanced Multiplex Optical Imaging Methods to Study the Tumor Micro-environment and Response to Cancer Immunotherapy
Ronald N. Germain, MD, PhD – NIAID, NIH

9:40 a.m.

Question & Answers
Ronald N. Germain, MD, PhD – NIAID, NIH

Session 303: Imaging Technologies

Time: 9:45 11:50 a.m.

Co-Chairs:

Carlo Bifulco, MD – Providence Portland Medical Center
Michael Dustin, PhD – The Kennedy Institute of Rheumatology

9:45 a.m.

Introduction

9:50 a.m.

Super-Resolution/ Fast Microscopy

10:05 a.m.

Cryoelectron Microscopy

10:20 a.m.

Multiplexed Imaging of Tissues- MIBI or CODEX

10:35 a.m.

Break

10:50 a.m.

DNA Microscopy

11:05 a.m.

Whole Body Imaging Technology

11:20 a.m.

Intravital Imaging

11:35 a.m.

Abstract Presentation

Session 304: Late-Breaking Abstract Session

Time:

11:50 a.m. 12:20 p.m.

11:50 a.m.

Abstract Presentation

12:05 p.m.

Abstract Presentation

Session 305: Sparkathon Update
Time:

12:20 12:35 p.m.

Lunch, Exhibits, and Poster Viewing
Time:

12:50 – 1:50 p.m.

Concurrent Rapid Oral Abstract Presentations - Basic
Time:

12:50 – 1:50 p.m.

Concurrent Rapid Oral Abstract Presentations - Clinical
Time:

12:50 – 1:50 p.m.

Session 306: Presidential Session
Time:

2:05 3:30 p.m.

Chair:

Mario Sznol, MD – Yale School of Medicine

2:05 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

2:10 p.m.

Abstract Presentation

2:25 p.m.

Abstract Presentation

2:40 p.m. Expert Discussant
2:50 p.m. Abstract Presentation
3:05 p.m. Abstract Presentation
3:20 p.m. Expert Discussant
Concurrent Session 307: Machine Learning Approaches and Applications
Time: 

3:45 5 p.m.

Co-Chairs:

Douglas Lauffenburger, PhD – Massachusetts Institute of Technology
Kurt A. Schalper, MD, PhD – Yale School of Medicine

3:45 p.m. Clinical Biomarkers
4 p.m. Deciphering the TME
4:15 p.m. Deep Learning Algorithms
4:30 p.m. Enhancing Predictors of Neoantigens and TCRs
Marta Łuksza, PhD – Mount Sinai
4:45 p.m. Abstract Presentation
Concurrent Session 308: Clinical Management
Time:

3:45 5 p.m.

Co-Chairs Marianne Davies, DNP, AOCNP – Yale School of Nursing
Elad Sharon, MD, MPH – National Cancer Institute

3:45 p.m. Response Criteria/ Patient Selection
Victoria L. Chiou, MD – Food & Drug Administration
4:05 p.m. Management of Patients in a Clinical Setting
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
4:25 p.m.

Combining Toxicity Management Strategies from a Program Perspective

4:45 p.m

Abstract Presentation

Concurrent Session 309: Single Agent Phase 1 Clinical Trials
Time: 3:45 5 p.m.
3:45 p.m. Abstract Presentation
4 p.m. Abstract Presentation
4:15 p.m. Abstract Presentation
4:30 p.m. Abstract Presentation
4:45 p.m. Abstract Presentation
Break
Time:

5 p.m.

Concurrent Session 310: Combination Phase 1-2 Clinical Trials

Time: 

5:15 – 6:30 p.m.

5:15 p.m.

Abstract Presentation

5:30 p.m.

Abstract Presentation

5:45 p.m.

Abstract Presentation

6 p.m.

Abstract Presentation

6:15 p.m.

Abstract Presentation

Concurrent Session 311: A Tale of Two Brain Tumors: Primary versus Metastatic CNS Tumors

Time:

5:15 – 6:30 p.m.

Co-Chairs:

Hideho Okada, MD, PhD – University of California, San Francisco
David Reardon, MD – Dana-Farber Cancer Institute

Concurrent Session 312: NK Cells: From Basic Science to Clinical Application

Time:

5:15 – 6:30 p.m.

Co-Chairs:

Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai
David Raulet, PhD – University of California, Berkeley

5:15 p.m.

Basic Science

5:35 p.m.

NK Cells and Bladder Cancer

5:55 p.m.

NK Cell Biology and Application to Therapy Options

6:15 p.m.

Abstract Presentation

Concurrent Session 313: Immunotherapy Advances in Skin Cancer

Time:

5:15 – 6:30 p.m.

Co-Chairs:

Shailender Bhatia, MD – University of Washington
Paolo Antonio Ascierto, MD – Istituto Nazionale Tumori-Fondazione 'G. Pascale'

5:15 p.m.

Immunotherapy Advances in Non-Melanoma Skin Cancer

5:35 p.m.

Advances in Melanoma Adjuvant Therapy: Implications for Clinical Practice and Future Research
Ahmad A. Tarhini, MD, PhD – Emory University and Winship Comprehensive Cancer Center

5:55 p.m.

Immunotherapy Advances in Melanoma

6:15 p.m.

Abstract Presentation

Concurrent Session 314: Tumor and Stromal Cell Biology

Time:

5:15 – 6:30 p.m.

Co-Chairs: 

Kwok-Kin Wong, MD, PhD – New York Langone Health
Neta Erez, PhD – Tel Aviv University

5:15 p.m.

Pancreatic Cancer

5:35 p.m.

Tumor Progression
Ashani Weeraratna, PhD – The Wistar Institute 

5:55 p.m.

Tumor Microenvironment

6:15 p.m.

Abstract Presentation

Award Ceremony

Time:

6:30 – 7 p.m.

Poster Reception

Time:

– 8:30 p.m.

The Checkpoints Band Party

Time:

8:30 – 11:30 p.m.

Sunday, Nov. 10, 2019

Session 400: Innovations in Cellular Therapy for Therapeutically Targeting Advanced Malignancies
Time:

8:05 10:15 a.m.

Co-Chairs:

Michel Sadelain, MD, PhD – Memorial Sloan Kettering Cancer Center
Ingunn Stromnes, PhD – University of Minnesota

8:05 a.m. Targeting Neoantigens
8:25 a.m. Dual Targeting CAR T cell
8:45 a.m. Early Stage Cellular Therapy Trials
Katyoun Rezvani, MD, PhD – University of Texas MD Anderson Cancer Center
9:05 a.m. Gene Editing
9:25 a.m. “Off the Shelf”
Jeffrey S. Miller, MD – University of Minnesota
9:45 a.m. Abstract Presentation
10 a.m. Abstract Presentation
Session 401: Update Session
Time: 10:30 10:45 a.m.
Session 402: Hot Topic Symposium
Time: 10:45 a.m. – 12:15 p.m.


​​​​​​​​​​​​​​​​​​​​